Mega Genomics (HKSE:06667) Net Cash per Share : HK$1.69 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Mega Genomics Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Mega Genomics's Net Cash per Share for the quarter that ended in Dec. 2023 was HK$1.69.

The historical rank and industry rank for Mega Genomics's Net Cash per Share or its related term are showing as below:

HKSE:06667' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 5.66 Med: 7.5 Max: 8.9
Current: 5.74

During the past 5 years, the highest Price-to-Net-Cash Ratio of Mega Genomics was 8.90. The lowest was 5.66. And the median was 7.50.

HKSE:06667's Price-to-Net-Cash is ranked better than
56.76% of 74 companies
in the Medical Diagnostics & Research industry
Industry Median: 7.07 vs HKSE:06667: 5.74

Mega Genomics Net Cash per Share Historical Data

The historical data trend for Mega Genomics's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mega Genomics Net Cash per Share Chart

Mega Genomics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Net Cash per Share

-0.99

-0.34

0.83

1.46

1.69

Mega Genomics Semi-Annual Data
	Dec19	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Cash per Share	Get a 7-Day Free Trial			0.83	1.36	1.46	1.61	1.69

Competitive Comparison of Mega Genomics's Net Cash per Share

For the Diagnostics & Research subindustry, Mega Genomics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mega Genomics's Price-to-Net-Cash Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Mega Genomics's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Mega Genomics's Price-to-Net-Cash falls into.

Mega Genomics Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Mega Genomics's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

	Net Cash per Share (A: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(566.894	-	165.943	-	0)	/	237.769
=	1.69

Mega Genomics's Net Cash per Share for the quarter that ended in Dec. 2023 is calculated as

	Net Cash per Share (Q: Dec. 2023 )
=	(Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(566.894	-	165.943	-	0)	/	237.769
=	1.69

Mega Genomics (HKSE:06667) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.

Mega Genomics Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Mega Genomics's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Mega Genomics (HKSE:06667) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Mega Genomics Ltd (HKSE:06667) » Definitions » Net Cash per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

North Garden Road, 401 Health Work, Haidian District, Beijing, CHN

Website

https://www.megagenomics.cn

Mega Genomics Ltd is a genetic testing platform company in China with a focus on consumer genetic testing and cancer screening services. The company has launched dozens of testing services, covering a wide range of fields such as nutrition and metabolism, cancer risk assessment, chronic disease susceptibility, cancer screening and infectious disease diagnosis, to meet consumers' growing preventive medical needs.

Executives

Guo Meiling	2101 Beneficial owner
Lin Lin	2101 Beneficial owner
Yu Rong	2501 Other
Infinite Galaxy Health Limited	2101 Beneficial owner
Mei Nian Investment Limited	2101 Beneficial owner
Kastle Limited	2501 Other
Mega Marvelous Limited	2501 Other
Yurong Technology Limited	2101 Beneficial owner
Niu Zhencai	2201 Interest of corporation controlled by you
Mei Nian Da Jian Kang Chan Ye Kong Gu Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing He He Heng Ye Ke Ji You Xian Gong Si	2201 Interest of corporation controlled by you
Bei Jing Shi Ji Yu Neng Ke Ji You Xian Gong Si	2501 Other
Tian Jin Shi Ji Yu Neng Qi Ye Guan Li He Huo Qi Ye You Xian He Huo	2101 Beneficial owner

Mega Genomics (HKSE:06667) Headlines

No Headlines